At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 303 enrolled
Drug / intervention
Vancomycin 1.1% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multicenter, Double-Masked, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Vancomycin Hydrochloride Ophthalmic Ointment 1.1% in Patients With Moderate to Severe Bacterial Conjunctivitis
In Brief
A Phase 3 clinical trial evaluating Vancomycin 1.1% and Placebo for Bacterial Conjunctivitis. Completed, enrolled 303 participants across 16 sites.
Detailed Summary
This is a Phase 3 study to evaluate the safety and efficacy of a vancomycin hydrochloride ophthalmic ointment dosed 4 times daily for 7 days compared to placebo (vehicle) in patients with moderate to severed Gram-positive bacterial conjunctivitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Conjunctivitis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartMay 2015
First PostedMay 2015
Primary CompletionMay 2018
TodayJul 2026
First PostedMay 4, 2015
Enrollment StartMay 1, 2015
Primary CompletionMay 31, 2018
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 11.2 years ago
Interventions
Vancomycin 1.1%drug
Vancomycin hydrochloride ophthalmic ointment 1.1%
Placebodrug
Placebo